Company profile
CYTOMX THERAPEUTICS, INC.
NASDAQ:CTMXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PACMILIMAB | phase2 | — | 3 | completed, terminated |
| PRALUZATAMAB RAVTANSINE | phase2 | — | 2 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05387265 | phase1 | terminated | 2022-05-16 | 2025-06-04 | CytomX Therapeutics | A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors |
| NCT06265688 | phase1 | recruiting | 2024-04-02 | 2027-11-30 | CytomX Therapeutics | First In Human Study of CX-2051 in Advanced Solid Tumors |
| NCT06462794 | phase1 | recruiting | 2024-08-28 | 2028-02-28 | CytomX Therapeutics | First In Human Study of CX-801 in Advanced Solid Tumors |
| NCT03013491 | phase1_2 | terminated | 2017-01-19 | 2020-10-27 | CytomX Therapeutics | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas |
| NCT03706274 | phase1 | withdrawn | 2020-01-01 | 2020-12-01 | CytomX Therapeutics | PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors |
FDA applications (0)
No records yet.